Technology | EP Mapping and Imaging Systems | July 01, 2019

VIVO 3-D Cardiac Mapping System Cleared by FDA

New non-invasive cardiac imaging system from Catheter Precision offers higher accuracy

VIVO 3-D Cardiac Mapping System Cleared by FDA

July 1, 2019 — Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO (View into Ventricular Onset) system for market release in the United States. VIVO is a pre-procedure planning tool that offers 3-D cardiac mapping to aid in localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. The novel VIVO system uses magnetic resonance imaging (MRI) or a computed tomography (CT) scan along with a standard 12-lead ΕCG to computer-generate color-coded 3-D mapping images of the heart to indicate the area of earliest activation.

The VIVO system consists of a handheld 3-D camera, and an off-the-shelf laptop computer with proprietary software. Using a 3-D photograph of the patient's chest, an MRI or CT (DICOM image), and a standard 12-lead ECG, the system generates a 3-D rendering of the patient's heart with superimposed color coding to indicate the area of earliest activation. VIVO uses lead positions, the chest photograph and DICOM data to determine the precise spatial relationships involved and, in that way, provide latest-generation cardiac mapping that can be used by a physician prior to conducting an electrophysiology study and subsequent ablation. The VIVO system has been shown to be 100 percent accurate (95 percent CI: 93.6 percent, 100 percent) in a prospective multi-center clinical trial. 

"VIVO is an important advance for patients who may require a cardiac ablation to better understand their irregular heart rhythms," said Hari Tandri, M.D., from Johns Hopkins University Hospital. "It is easy to use, fits into our standard workflow and is not invasive. Knowing the arrhythmia foci in advance should reduce mapping time, potentially saving procedure time and cost.  My experience with the VIVO to date has shown it to be an accurate, easy-to-use system that has the potential to significantly improve 3-D cardiac mapping technology for ventricular arrhythmia mapping."

For more information: www.catheterprecision.com


Related Content

News

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
News

Oct. 18, 2024 — Boston Scientific Corp. recently announced it has received U.S. Food and Drug Administration (FDA) ...

Home October 21, 2024
Home
News

May 15, 2024 —CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
News

May 13, 2024 — Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Subscribe Now